Top Markets
#1 Status Status +21.05%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.55%
#3 Fake World Assets Fake World Assets +14.92%
#4 Ontology Gas Ontology Gas +12.78%
#5 GoPlus Security GoPlus Security +12.22%
#6 DMT-NAT DMT-NAT +8.79%
#7 Nillion Nillion +6.92%
#8 Provenance Blockchain Provenance Blockchain +6.68%
#9 Janction Janction +6.46%
#10 Bedrock Bedrock +5.82%
Coin of the day
Status Status
Settings
Language
ENGLISH
Currency
USD
Theme
Kineta, Inc. Kineta, Inc.

Kineta, Inc.

KA
Rank in Stocks #34154
Kineta, Inc. is a clinical-stage biotechnology firm dedicated to developing... Kineta, Inc. is a clinical-stage biotechnology firm dedicated to developing immunotherapies, with a focus on oncology, neuroscience, and biodefense applications. The company engages in partnerships with a variety of entities, including private companies, government bodies, and other industry stakeholders. Among its significant strategic collaborators are Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Established in 2007, Kineta, Inc. was previously known as Lecura, Inc. and has its base of operations in Seattle, Washington.
Share Price
$0.617
Last synced: 2024-10-14
Market Cap
$6.13M
Change (1 day)
0.49%
Change (1 year)
0.00%
Country
US
Trade Kineta, Inc. (KA)

Category

Healthcare
Revenue for Kineta, Inc. (KA)
Revenue in Mar 2025 TTM: $4.34M
According to Kineta, Inc. latest financial reports the company's current revenue (TTM) is $4.34M. In 2023 the company made a revenue of $5.44M an increase over the revenue in the year 2022 that was $1.95M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Kineta, Inc. from 2015 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $4.34M 0.00%
2024 0.00 -100.00%
2023 $5.44M 178.65%
2022 $1.95M -78.52%
2021 $9.09M -13.32%
2020 $10.49M 109.76%
2019 $5.00M 76.06%
2018 $2.84M -46.83%
2017 $5.34M -36.30%
2016 $8.38M 94.43%
2015 $4.31M 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 290,916.60%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 138,703.30%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B 232,974.84%
BE